Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes

REFERENCES

• Lin J.H., Lu A.Y.H. Inhibition and Induction of Cytochrome P450 and the Clinical Implications. Clin. Pharmacokinet. 1998; 35: 361–390
   PubMed Web of Science ®Google Scholar
• Ferslew K.E., Hagardorn A.N., Harlan G.C., McCormick W.F. A Fatal Drug Interaction between Clozapine and Fluoxetine. J. Forensic Sci. 1998; 43: 1082–1085
   PubMed Web of Science ®Google Scholar
• Kudo K., Imamura T., Jitsufuchi N., Zhang X.X., Tokunaga H., Nagata T. Death Attributed to the Toxic Interaction of Triazolam, Amitryptyline and Other Psychotropic Drugs. Forensic Sci. Int. 1997; 86: 35–41
   PubMed Web of Science ®Google Scholar
• White R.E., Coon M.J. Oxygen Activation by Cytochrome P450. Annu. Rev. Biochem. 1980; 49: 315–356
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano P.R., Correia M.A. Inhibition of Cytochrome P450 Enzymes. Cytochrome P450: Structure, Mechanism, and Biochemistry, P.R. Ortiz de Montellano. 2nd Ed., Plenum Press, New York 1995; 305–364
   Google Scholar
• Guengerich F.P. Inhibition of Drug Metabolizing Enzymes: Molecular and Biochemical Aspects. Handbook of Drug Metabolism, T.F. Woolf. Marcel Dekker, New York 1999; 203–227
   Google Scholar
• Lin J.H., Chen I.-W., Chiba M., Nishime J.A., de Luna F.A. Route-Dependent Nonlinear Pharmacokinetics of a Novel HIV Protease Inhibitor: Involvement of Enzyme Inactivation. Drug Metab. Dispos. 2000; 28: 460–466
   PubMed Web of Science ®Google Scholar
• Segel I.H. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. Wiley and Sons, New York 1975
   Google Scholar
• Cornish-Bowden A. Fundamentals of Enzyme Kinetics. Butterworths, London 1979
   Google Scholar
• Bronson D.D., Daniels D.M., Dixon J.T., Redick C.C., Haaland P.D. Virtual Kinetics: Using Statistical Experimental Design for Rapid Analysis of Enzyme Inhibitor Mechanisms. Biochem. Pharmacol. 1995; 50: 823–831
   PubMed Web of Science ®Google Scholar
• Renwick A.G. Toxicokinetics: Pharmacokinetics in Toxicology. Principles and Methods of Toxicology, A.W. Hayes. 4th Ed., Raven Press, New York 2001; 137–192
   Google Scholar
• Black D.J., Kunze K.L., Wienkers L.C., Gidal B.E., Seaton T.L., McDonnell N.D., Evans J.S., Bauwens J.E., Trager W.F., Warfarin-Fluconazole V. A Metabolically Based Drug Interaction: In Vivo Studies. Drug. Metab. Dispos. 1996; 24: 422–428
   PubMed Web of Science ®Google Scholar
• Schenkman J.B., Sligar S.G., Cinti D.L. Substrate Interactions with Cytochrome P-450. Pharmacol. Ther. 1981; 12: 43–71
   PubMed Web of Science ®Google Scholar
• Guengerich F.P. Oxidation–Reduction Properties of Rat Liver Cytochromes P450 and NADPH-Cytochrome P-450 Reductase Related to Catalysis in Reconstituted Systems. Biochemistry 1983; 22: 2811–2820
   PubMed Web of Science ®Google Scholar
• Franklin M.R. The Enzymic Formation of a Methylenedioxyphenyl Derivative Exhibiting an Isocyanide-like Spectrum with Reduced Cytochrome P-450 in Hepatic Microsomes. Xenobiotica 1971; 1: 581–591
   PubMedGoogle Scholar
• Elcombe C.R., Bridges J.W., Gray T.J.B., Nimmo-Smith R.H., Netter K.J. Studies on the Interaction of Safrole with Rat Hepatic Microsomes. Biochem. Pharmacol. 1975; 24: 1427–1433
   Web of Science ®Google Scholar
• Murray M., Hetnarski K., Wilkinson C.F. Selective Inhibitory Interactions of Alkoxymethylene-Dioxybenzenes Towards Mono-Oxygenase Activity in Rat Hepatic Microsomes. Xenobiotica 1985; 15: 369–379
   PubMed Web of Science ®Google Scholar
• Mansuy D., Gans P., Chottard J.-C., Bartoli J.-F. Nitrosoalkanes as Fe(II) Ligands in the 455-nm-Absorbing Cytochrome P-450 Complexes Formed from Nitroalkanes in Reducing Conditions. Eur. J. Biochem. 1977; 76: 607–615
   PubMedGoogle Scholar
• Ator M.A., Ortiz de Montellano P.R. Mechanism-Based (Suicide) Enzyme Inactivation. The Enzymes: Mechanisms of Catalysis, D.S. Segman, P.D. Boyer. 3rd Ed., Academic Press, New York 1990; Vol. 19: 214–282
   Google Scholar
• Silverman R.B. Mechanism-Based Enzyme Inactivation: Chemistry and Biology. CRC Press, Boca Raton, FL 1988
   Google Scholar
• Kent U.M., Jushchyshyn M.I., Hollenberg P.F. Mechanism-Based Inactivators as Probes of Cytochrome P450 Structure and Function. Curr. Drug. Metab. 2001; 2: 215–244
   PubMed Web of Science ®Google Scholar
• He K., Iyer K., Hayes R.N., Sinz M.W., Woolf T.F., Hollenberg P.F. Inactivation of P450 3A4 by Bergamottin, a Component of Grapefruit Juice. Chem. Res. Toxicol. 1998; 11: 252–259
   PubMed Web of Science ®Google Scholar
• Wang E., Walsh C. Suicide Substrates for the Alanine Racemase of Eschericia coli B. Biochemistry 1978; 17: 1313–1321
   PubMed Web of Science ®Google Scholar
• Whitlock J.P., Jr., Denison M.S. Induction of Cytochrome P450 Enzymes that Metabolize Xenobiotics. Cytochromes P450: Structure, Mechanism, and Biochemistry, P.R. Ortiz de Montellano. 2nd Ed., Plenum Press, New York 1995; 367–398
   Google Scholar
• Watkins P.B., Wrighton S.A., Scheutz E.G., Maurel P., Guzelian P.S. Macrolide Antibiotics Inhibit the Degradation of the Glucocorticoid-Responsive Cytochrome P-450p in Rat Hepatocytes In Vivo and in Primary Monolayer Culture. J. Biol. Chem. 1986; 261: 6264–6271
   PubMed Web of Science ®Google Scholar
• Conney A.H., Miller E.C., Miller J.A. The Metabolism of Methylated Aminoazo Dyes. Evidence for Induction of Enzyme Synthesis in the Rat by 3-Methylcholanthrene. Cancer Res. 1956; 16: 450–459
   PubMed Web of Science ®Google Scholar
• Ronis M.J.J., Ingelman-Sundberg M. Induction of Human Drug-Metabolizing Enzymes: Mechanisms and Implications. Handbook of Drug Metabolism, T.F. Woolf. Marcel Dekker, New York 1999; 239–262
   Google Scholar
• Poland A.P., Glover E., Kende A.S. Sterospecific, High Affinity Binding of 2,3,7,8-Tetrachlorodibenzo-p-dioxin by Hepatic Cytosol: Evidence that the Binding Species Is a Receptor for the Induction of Aryl Hydrocarbon Hydroxylase. J. Biol. Chem. 1976; 251: 4936–4946
   PubMed Web of Science ®Google Scholar
• Perdew G.H. Association of the Ah receptor with the 90 kDa Heat Shock Protein. J. Biol. Chem. 1988; 263: 13802–13805
   PubMed Web of Science ®Google Scholar
• Hankinson O. A Genetic Analysis of Processes Regulating Cytochrome P450 1A1 Expression. Adv. Enzyme Regul. 1994; 34: 159–171
   PubMedGoogle Scholar
• Mathis J.M., Houser W.H., Bresnick E., Cidlowski J.A., Hines R.N., Prough R.A., Simpson E.R. Glucocorticoid Regulation of the Rat Cytochrome P450c (P4501A1) Gene: Receptor Binding within Intron I. Arch. Biochem. Biophys. 1989; 269: 93–105
   PubMed Web of Science ®Google Scholar
• Boucher P.D., Hines R.N. In Vitro Binding and Functional Studies Comparing Human CYP1A1 Regulatory Element with the Orthologous Sequences from Rodent Genes. Carcinogenesis 1995; 16: 383–392
   PubMed Web of Science ®Google Scholar
• Boucher P.D., Piechocki M.P., Hines R.N. Partial Characterization of the Human CYP1A1 Negatively Acting Transcription Factor and Mutational Analysis of Its Cognate DNA Recognition Sequence. Mol. Cell. Biol. 1995; 15: 5144–5155
   PubMed Web of Science ®Google Scholar
• Quattrochi L.C., Vu T., Tukey R.H. The Human CYP1A2 Gene and Induction by 3-Methylcholanthrene. A Region of DNA Which Supports Ah Receptor Binding and Promotor Specific Induction. J. Biol. Chem. 1994; 269: 6949–6954
   PubMed Web of Science ®Google Scholar
• Waxman D.J., Azaroff L. Phenobarbital Induction of Cytochrome P-450 Gene Expression. Biochem. J. 1992; 281: 577–592
   PubMed Web of Science ®Google Scholar
• Waxman D.J. P450 Gene Induction by Structurally Diverse Xenochemicals: Central Role of Nuclear Receptors CAR, PXR, and PPAR, Arch. Biochem. Biophys. 1999; 369: 11–23
   Web of Science ®Google Scholar
• Honkakoski P., Negishi M. Regulation of Cytochrome P450 (CYP) Genes by Nuclear Receptors. Biochem. J. 2000; 347: 321–337
   PubMed Web of Science ®Google Scholar
• Ronis M.J.J., Lindros K.O., Ingelman-Sundberg M. The CYP2E Family. Cytochromes P450: Metabolic and Toxicological Aspects, C. Ioannides. CRC Press, Boca Raton, FL 1996; 211–239
   Google Scholar
• Kim S.G., Shehin S.E., States C., Novak R.F. Evidence for Increased Translational Efficiency in the Induction of P450 IIE1 by Solvents: Analysis of P450 IIE1 mRNA Polyribosomal Distribution. Biochem. Biophys. Res. Commun. 1990; 172: 767–774
   PubMed Web of Science ®Google Scholar
• Kraner J.C., Lasker J.M., Corcoran J.B., Ray S.D., Raucy J.L. Induction of P450 2E1 in Isolated Rabbit Hepatocytes: Role of Increased Protein and mRNA Synthesis. Biochem. Pharmacol. 1993; 45: 1483–1488
   PubMed Web of Science ®Google Scholar
• McGee R.E., Jr., Ronis M.J.J., Cowherd R.M., Ingelman-Sundberg M., Badger T.M. Characterization of Cytochrome P450 2E1 Induction in a Rat Hepatoma FGC-4 Cell Model by Ethanol. Biochem. Pharmacol. 1994; 48: 1823–1833
   PubMed Web of Science ®Google Scholar
• Ged C., Rouillon J.M., Pichard L., Combalbert J., Bressot N., Bories P., Michel H., Beaune P., Maurel P. The Increase in Urinary Excretion of 6(-Hydroxycortisol) as a Marker of Human Hepatic Cytochrome P450IIIA Induction. Br. J. Clin. Pharmacol. 1989; 28: 373–387
   PubMed Web of Science ®Google Scholar
• Kolars J.C., Schmiedlin-Ren P., Scheutz J.D., Fang C., Watkins P.B. Identification of Rifampicin-Inducible P450IIA4 (CYP3A4) in Human Small Bowel Enterocytes. J. Clin. Invest. 1992; 90: 1871–1878
   PubMed Web of Science ®Google Scholar
• Fromm M.F., Dilger K., Busse D., Kroemer H., Eichelbaum M., Klotz U. Gut Wall Metabolism of Verapamil in Older People: Effects of Rifampicin-Mediated Enzyme Induction. Br. J. Clin. Pharmacol. 1998; 45: 247–255
   PubMed Web of Science ®Google Scholar
• Backman J.T., Olkkola K.T., Neuvonen P.J. Rifampicin Drastically Reduces Plasma Concentrations and Effects of Oral Midazolam. Clin. Pharmacol. Ther. 1996; 59: 7–13
   PubMed Web of Science ®Google Scholar
• Hebert M.F., Roberts J.P., Prueksaritanont T., Benet L.Z. Bioavailability of Cyclosporin with Concomitant Rifampin Administration is Markedly Less Than Predicted by Hepatic Enzyme Induction. Clin. Pharmacol. Ther. 1992; 52: 453–457
   PubMed Web of Science ®Google Scholar
• Chang T.K., Yu L., Maurel P., Waxman D.J. Enhanced Cyclophosphamide and Ifosphamide Activation in Primary Human Hepatocyte Cultures: Response to Cytochrome P-450 Inducers and Autoinduction by Oxazaphosphorines. Cancer Res. 1997; 57: 1946–1954
   PubMed Web of Science ®Google Scholar
• Anders M. Enhancement and Inhibition of Microsomal Drug Metabolism. Prog. Drug. Res. 1973; 17: 11–32
   Google Scholar
• Cinti D.L. Agents Activating the Liver Microsomal Mixed Function Oxidase System. Pharmacol. Ther. 1978; 2: 727–749
   Web of Science ®Google Scholar
• Holtzman J.L. The Role of the Stimulation of NADPH-Cytochrome P-450 Reductase Activity in Hepatic, Microsomal Mixed Function Oxidase Activity. Pharmacol. Ther. 1979; 4: 601–627
   Web of Science ®Google Scholar
• Leibman K. Effects of Metyrapone on Liver Microsomal Drug Oxidations. Mol. Pharmacol. 1969; 5: 1–9
   PubMed Web of Science ®Google Scholar
• Anders M. Acetone Enhancement of Microsomal Aniline para-Hydroxylase Activity. Arch. Biochem. Biophys. 1968; 126: 269–275
   PubMed Web of Science ®Google Scholar
• Huang M.-T., Johnson E., Muller-Eberhard V., Koop D.R., Coon M.J., Conney A.H. Specificity in the Activation and Inhibition by Flavonoids of Benzo[a]pyrene Hydroxylation by Cytochrome P-450 Isozymes from Rabbit Liver Microsomes. J. Biol. Chem. 1981; 256: 10897–10901
   PubMed Web of Science ®Google Scholar
• Bauer E., Guo Z., Ueng Y.-F., Bell L.C., Zeldin D., Guengerich F.P. Oxidation of Benzo[a]pyrene by Recombinant Cytochrome P450 Enzymes. Chem. Res. Toxicol. 1995; 8: 136–142
   PubMed Web of Science ®Google Scholar
• Ueng Y.-F., Kuwabara T., Chun Y.-J., Guengerich F.P. Coooperativity in Oxidations Catalyzed by Cytochrome P450 3A. Biochemistry 1997; 36: 370–381
   PubMed Web of Science ®Google Scholar
• Guengerich F.P. Cytochrome P-450 3A4: Regulation and Role in Drug Metabolism. Annu. Rev. Pharmacol. Toxicol. 1999; 39: 1–17
   PubMed Web of Science ®Google Scholar
• Ekins S., Ring B.J., Binkley S.N., Hall S.D., Wrighton S.A. Autoactivation and Activation of the Cytochrome P450s. Int. J. Clin. Pharmacol. Ther. 1998; 36: 642–651
   PubMed Web of Science ®Google Scholar
• Tang W., Stearns R.A. Heterotropic Cooperativity of Cytochrome P450 3A4 and Potential Drug–Drug Interactions. Curr. Drug Metab. 2001; 2: 185–198
   PubMed Web of Science ®Google Scholar
• Huang M.-T., Chang R.L., Fortner J.G., Conney A.H. Studies on the Mechanism of Activation of Microsomal Benzo[a]pyrene Hydroxylation by Flavonoids. J. Biol. Chem. 1981; 256: 6829–6836
   PubMed Web of Science ®Google Scholar
• Harlow G.R., Halpert J.R. Analysis of Human Cytochrome P450 3A4 Cooperativity. Construction and Characterization of a Site-Directed Mutant That Displays Hyperbolic Steroid Hydroxylation Kinetics. Proc. Natl Acad. Sci. USA 1998; 95: 6636–6641
   PubMed Web of Science ®Google Scholar
• Korzekwa K.R., Krishnamachary N., Shou M., Ogai A., Parise R.A., Rettie A.E., Gonzalez F.J., Tracey T.S. Evaluation of Atypical Cytochrome P450 Kinetics with Two-Substrate Models: Evidence That Multiple Substrates Can Simultaneously Bind to Cytochrome P450 Active Sites. Biochemistry 1998; 37: 4137–4147
   PubMed Web of Science ®Google Scholar
• Domanski T.L., He Y.-A., Harlow G.R., Halpert J.R. Dual Role of Human Cytochrome P450 3A4 Residue Phe-304 in Substrate Specificity and Cooperativity. J. Pharmacol. Exp. Ther. 2000; 293: 585–591
   PubMed Web of Science ®Google Scholar
• Atkins W.M., Wang R.W., Lu A.Y.H. Allosteric Behavior in Cytochrome P450-Dependent In Vitro Drug–Drug Interactions: A Prospective Based on Conformational Dynamics. Chem. Res. Toxicol. 2001; 14: 338–347
   PubMed Web of Science ®Google Scholar